Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

This study has been terminated.
(subject accrual and data analysis is completed.)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00002778
First received: November 1, 1999
Last updated: July 19, 2011
Last verified: April 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2010
  Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)